Table 2 mRNA expression of bone sialoprotein (BSP) in primary tumours and healthy tissue

From: Bone sialoprotein: a multifunctional regulator of bone remodelling and tumour progression

Cancer (Subtype)

mRNA expression of bone sialoprotein

Source (n)

Quantification

Reference

 

Normal (n)

Tumour (n)

   

Bone (OS)

+

+++* (85)

TARGET database

 

90

Bone (OS)

–/o

+++*

Matched tissue (15)

 

90

Brain

(HGG)

(LGG)

++

+++*a (30)

++* (25)

Patients

RT-PCR

91

Brain (GBM)

++

+++NA

TCGA

 

158

Breast

(Ductal)

(Lobular)

o

+++* (31)

+ (31)

Matched tissue (53)

Cancer profiling array

49

Breast

with bone MET and non-bone MET

 

+++

(6)

Patients

RNA sequencing

18

Breast

 

+++

GEPIA2 database

 

18

Breast

 

+/++/+++

(18)

Patients

RT-PCR

169

Colon

o

+++*

Matched tissue (39)

Cancer profiling array

49

Gastric (stomach)

o

+++*

Matched tissue (27)

Cancer profiling array

49

Kidney

o

++*

Matched tissue (21)

Cancer profiling array

49

Bone marrow (MM)

 

++/+++ (5)

 

In situ hybridisation

72

Lung

o

+NS

Matched tissue (21)

Cancer profiling array

49

Lung

(LUAD)

(LUSC)

o

o

+++*

+++*

TCGA

 

92

Lung (LUAD)

 

80% +/++/+++ (10)

Patients

RT-PCR

79

Ovary

o

++NS

Matched tissue (17)

Cancer profiling array

49

Pancreas (PDAC)

41% o

59% –

(27)

86% +* (29)

Patients

Organ donors

RT-PCR

69

Prostate

o

++

Matched tissue (4)

Cancer profiling array

86

Prostate

–/o

+++ (8)

Patients

In situ hybridisation

71

Rectum

o

+++*

Cancer profiling array

 

49

Thyroid

o

++*

Cancer profiling array

 

49

Uterine (Endometrium)

o

+NS

Cancer profiling array

 

49

  1. – undetectable/no expression, o very low expression, + low expression, ++ moderate expression, +++ high expression
  2. GBM glioblastoma, GEPIA2 gene expression profiling interactive analysis 2, HGG high-grade glioma, LGG low-grade glioma, LUAD lung adenocarcinoma, LUSC lung squamous cell, MET metastasis, MM multiple myeloma, NA not available, NS non-significant, OS osteosarcoma, PDAC pancreatic ductal carcinoma, TARGET therapeutically applicable research to generate effective treatments, TCGA the cancer genome atlas
  3. *P < 0.05 compared to control
  4. acompared to LGG